Latest Breaking News On - Stoke therapeutic - Page 1 : vimarsana.com

HC Wainwright Brokers Cut Earnings Estimates for Stoke Therapeutics, Inc (NASDAQ:STOK)

HC Wainwright Brokers Cut Earnings Estimates for Stoke Therapeutics, Inc (NASDAQ:STOK)
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United statesSg americas securitiesStoke therapeutics incJpmorgan chase coStoke therapeutics company profileMirae asset global investments coSecurities exchange commissionDorsey whitney trustCanaccord genuity groupNeedham companyYork mellon corpStoke therapeuticsFree reportStoke therapeuticGenuity groupTherapeutics trading down

Stoke Therapeutics, Inc (NASDAQ:STOK) Forecasted to Post FY2028 Earnings of $0 17 Per Share

Stoke Therapeutics, Inc (NASDAQ:STOK) Forecasted to Post FY2028 Earnings of $0 17 Per Share
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesStephenj tulipanoStoke therapeutics incStoke therapeutics company profileJpmorgan chase coCantor fitzgeraldNeedham companyCanaccord genuity groupCapital partnersMirae asset global investments coSecurities exchange commissionStoke therapeuticsFree reportStoke therapeuticGet free reportTherapeutics stock down

Wall Street Breakfast Podcast: Lucid Secures $1B Investment

Wall Street Breakfast Podcast: Lucid Secures $1B Investment
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Saudi arabiaUnited statesBaker hughesShantanu narayenEd bastianLe peuchOlivier le peuchAdam neumannAdam jonasMary barraDan loebLucid group incAyar third investment companyMorgan stanleyLucid groupCallon petroleum

Stoke Therapeutics (NASDAQ:STOK) Given New $14 00 Price Target at Cantor Fitzgerald

Stoke Therapeutics (NASDAQ:STOK) Given New $14 00 Price Target at Cantor Fitzgerald
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesBarry tichoJonathan allanCantor fitzgeraldCanaccord genuity groupNeedham companyHong kong ltdEnsign peak advisors incStoke therapeutics incGreat west life assurance coCredit suisse groupStoke therapeuticsFree reportStoke therapeuticGenuity group

Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $14 00 at Cantor Fitzgerald

Stoke Therapeutics (NASDAQ:STOK – Free Report) had its target price decreased by Cantor Fitzgerald from $18.00 to $14.00 in a research note released on Tuesday morning, Marketbeat.com reports. Cantor Fitzgerald currently has an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Stoke Therapeutics’ FY2023 earnings at ($2.42) EPS and FY2024 earnings at […]

United statesBarry tichoJonathan allanStoke therapeutics incMetlife investment managementNeedham companyStoke therapeutics company profileCanaccord genuity groupCantor fitzgeraldSecurities exchange commissionYork mellon corpJpmorgan chase coSwiss national bankStoke therapeuticsFree reportStoke therapeutic